Stem cell therapy for systemic sclerosis
Treatments studied
Part of Skin clinical trials.
This trial tests whether stem cells from umbilical cord blood can help treat systemic sclerosis (scleroderma). The goal is to see if this treatment can improve skin thickening and overall symptoms for people who haven't had success with standard therapies.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 65 years old
- Have a diagnosis of diffuse systemic sclerosis (a type of scleroderma) for 5 years or less
- Have tried at least two standard treatments (like corticosteroids, immunosuppressants, or biologic agents) without enough benefit
- Have a skin thickness score between 10 and 30 (your doctor can measure this)
- Not have certain severe heart, lung, or kidney problems, and be free of active infections or recent cancer
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental cell therapy (UTAA91) for people with hard-to-treat scleroderma. The goal is to see if this treatment can help when other options haven't worked.
This trial tests an investigational drug called efgartigimod in people with systemic sclerosis (scleroderma). The goal is to see if it can safely reduce skin thickening and improve overall health. You might qualify if your skin is moderately affected and you have certain antibodies in your blood.
This trial tests a new treatment, UTAA91 injection, for people with moderate-to-severe systemic sclerosis that hasn't improved with standard therapies. It may offer an option when other treatments have failed or aren't available.
This study looks at how a new drug affects skin scarring (fibrosis) in people with systemic sclerosis (SSc), a rare autoimmune disease. It aims to understand if this drug can help reduce the skin thickening and immune changes caused by SSc.
This study uses skin samples from people with scleroderma, their relatives, and healthy volunteers to create stem cells in a lab. The goal is to learn more about the disease and find better ways to treat it.
This study tests a new medicine (called GB261) given as an infusion for people with systemicsclerosis (scleroderma) that affects the skin widely. The goal is to see if it can reduce skin thickening and improve symptoms.
Hear when a new Systemic Sclerosis (SSc) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.